Deutsche Bank Ag\ Metacrine, Inc. Transaction History

Deutsche Bank Ag\

  • $240 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 11, 2021
SELL
$3.37 - $5.73 $14,295 - $24,306
-4,242 Closed
0 $0
Q1 2021

May 13, 2021
SELL
$6.2 - $11.0 $2,455 - $4,356
-396 Reduced 8.54%
4,242 $26,000
Q4 2020

Feb 16, 2021
BUY
$7.75 - $11.42 $35,944 - $52,965
4,638 New
4,638 $36,000

Others Institutions Holding MTCR

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About Metacrine, Inc.

MTCR Quotes by TradingView
  • Ticker MTCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,569,500
  • Description
  • Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
More about MTCR
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email